Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome

Daniel Porru, M. Cervigni, L. Nasta, F. Natale, R. Lo Voi, C. Tinelli, B. Gardella, A. Anghileri, A. Spinillo, B. Rovereto

Research output: Contribution to journalArticle

Abstract

Objectives- The aim of our study was to test the effect of a more viscous compound than existent hyaluronic acid formulation in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients. Methods- A total of 23 female patients completed the study. Patients received endovesical administration of hyaluronic acid and chondroitin sulfate in normal saline, 40 ml, weekly for 12 weeks and then bi-weekly for 6 months, if there was initial response. Results- After 12 weeks treatment both Interstitial Cystitis Symptom and Problem Index (ICS1/ICPI), pelvic pain and Urgency/Frequency Symptom Scale (PUF) showed a mean significant improvement, which was maintained thereafter. The average number of voidings and mean voiding volumes revealed significant improvement after the 12 weeks' treatment period, with a significant reduction and increase, respectively. Mean voiding volume increased from 143 ml to 191, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15,5 to 14). VAS values decreased from 5,4 to 3,6 (pain) and from 6,0 to 3,5 (urgency) after the treatment cycle, showing a significant improvement. Conclusions- In our preliminary experience, the administration of intravesical hyaluronic acid plus chondroitine sulphate appears to be a safe and efficacious method of treatment in IC/PBS.

Original languageEnglish
Pages (from-to)126-129
Number of pages4
JournalReviews on Recent Clinical Trials
Volume3
Issue number2
DOIs
Publication statusPublished - May 2008

Fingerprint

Interstitial Cystitis
Chondroitin Sulfates
Hyaluronic Acid
Therapeutics
Intravesical Administration
Pelvic Pain
Glycosaminoglycans
Sulfates
Pain

Keywords

  • Chondroitine sulfate
  • Hyaluronic acid
  • Interstitial cystitis
  • Intravesical treatment
  • Painful bladder syndrome

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology

Cite this

Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome. / Porru, Daniel; Cervigni, M.; Nasta, L.; Natale, F.; Voi, R. Lo; Tinelli, C.; Gardella, B.; Anghileri, A.; Spinillo, A.; Rovereto, B.

In: Reviews on Recent Clinical Trials, Vol. 3, No. 2, 05.2008, p. 126-129.

Research output: Contribution to journalArticle

@article{ebda3d6c2df54a28942f2760cc209af0,
title = "Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome",
abstract = "Objectives- The aim of our study was to test the effect of a more viscous compound than existent hyaluronic acid formulation in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients. Methods- A total of 23 female patients completed the study. Patients received endovesical administration of hyaluronic acid and chondroitin sulfate in normal saline, 40 ml, weekly for 12 weeks and then bi-weekly for 6 months, if there was initial response. Results- After 12 weeks treatment both Interstitial Cystitis Symptom and Problem Index (ICS1/ICPI), pelvic pain and Urgency/Frequency Symptom Scale (PUF) showed a mean significant improvement, which was maintained thereafter. The average number of voidings and mean voiding volumes revealed significant improvement after the 12 weeks' treatment period, with a significant reduction and increase, respectively. Mean voiding volume increased from 143 ml to 191, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15,5 to 14). VAS values decreased from 5,4 to 3,6 (pain) and from 6,0 to 3,5 (urgency) after the treatment cycle, showing a significant improvement. Conclusions- In our preliminary experience, the administration of intravesical hyaluronic acid plus chondroitine sulphate appears to be a safe and efficacious method of treatment in IC/PBS.",
keywords = "Chondroitine sulfate, Hyaluronic acid, Interstitial cystitis, Intravesical treatment, Painful bladder syndrome",
author = "Daniel Porru and M. Cervigni and L. Nasta and F. Natale and Voi, {R. Lo} and C. Tinelli and B. Gardella and A. Anghileri and A. Spinillo and B. Rovereto",
year = "2008",
month = "5",
doi = "10.2174/157488708784223817",
language = "English",
volume = "3",
pages = "126--129",
journal = "Reviews on Recent Clinical Trials",
issn = "1574-8871",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of interstitial cystitis/painful bladder syndrome

AU - Porru, Daniel

AU - Cervigni, M.

AU - Nasta, L.

AU - Natale, F.

AU - Voi, R. Lo

AU - Tinelli, C.

AU - Gardella, B.

AU - Anghileri, A.

AU - Spinillo, A.

AU - Rovereto, B.

PY - 2008/5

Y1 - 2008/5

N2 - Objectives- The aim of our study was to test the effect of a more viscous compound than existent hyaluronic acid formulation in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients. Methods- A total of 23 female patients completed the study. Patients received endovesical administration of hyaluronic acid and chondroitin sulfate in normal saline, 40 ml, weekly for 12 weeks and then bi-weekly for 6 months, if there was initial response. Results- After 12 weeks treatment both Interstitial Cystitis Symptom and Problem Index (ICS1/ICPI), pelvic pain and Urgency/Frequency Symptom Scale (PUF) showed a mean significant improvement, which was maintained thereafter. The average number of voidings and mean voiding volumes revealed significant improvement after the 12 weeks' treatment period, with a significant reduction and increase, respectively. Mean voiding volume increased from 143 ml to 191, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15,5 to 14). VAS values decreased from 5,4 to 3,6 (pain) and from 6,0 to 3,5 (urgency) after the treatment cycle, showing a significant improvement. Conclusions- In our preliminary experience, the administration of intravesical hyaluronic acid plus chondroitine sulphate appears to be a safe and efficacious method of treatment in IC/PBS.

AB - Objectives- The aim of our study was to test the effect of a more viscous compound than existent hyaluronic acid formulation in helping to restore a defective glycosaminoglycan layer, and therefore in improving Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS) symptoms when administered intravesically in IC/PBS patients. Methods- A total of 23 female patients completed the study. Patients received endovesical administration of hyaluronic acid and chondroitin sulfate in normal saline, 40 ml, weekly for 12 weeks and then bi-weekly for 6 months, if there was initial response. Results- After 12 weeks treatment both Interstitial Cystitis Symptom and Problem Index (ICS1/ICPI), pelvic pain and Urgency/Frequency Symptom Scale (PUF) showed a mean significant improvement, which was maintained thereafter. The average number of voidings and mean voiding volumes revealed significant improvement after the 12 weeks' treatment period, with a significant reduction and increase, respectively. Mean voiding volume increased from 143 ml to 191, which apparently was not reflected in a corresponding reduction of number of daily voids (from 15,5 to 14). VAS values decreased from 5,4 to 3,6 (pain) and from 6,0 to 3,5 (urgency) after the treatment cycle, showing a significant improvement. Conclusions- In our preliminary experience, the administration of intravesical hyaluronic acid plus chondroitine sulphate appears to be a safe and efficacious method of treatment in IC/PBS.

KW - Chondroitine sulfate

KW - Hyaluronic acid

KW - Interstitial cystitis

KW - Intravesical treatment

KW - Painful bladder syndrome

UR - http://www.scopus.com/inward/record.url?scp=46749158369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46749158369&partnerID=8YFLogxK

U2 - 10.2174/157488708784223817

DO - 10.2174/157488708784223817

M3 - Article

C2 - 18474023

AN - SCOPUS:46749158369

VL - 3

SP - 126

EP - 129

JO - Reviews on Recent Clinical Trials

JF - Reviews on Recent Clinical Trials

SN - 1574-8871

IS - 2

ER -